BAX 826

Drug Profile

BAX 826

Alternative Names: Bax-826; BAX826; Polysialylated rFVIII; PSA-FVIII - Shire/Xenetic Biosciences; PSA-rFVIII; SHP 656

Latest Information Update: 21 Nov 2016

Price : $50

At a glance

  • Originator Baxter International; Xenetic Biosciences
  • Developer Shire; Xenetic Biosciences
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Haemophilia
  • Phase I Haemophilia A

Most Recent Events

  • 15 Nov 2016 Phase-II clinical trials in Haemophilia before September 2016
  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 04 Mar 2016 Phase-I clinical trials in Haemophilia A in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top